RATIONALE: 15-Deoxy-Δ-prostaglandin (15d-PG)J(2) is an electrophilic oxidant that dilates the coronary vasculature. This lipid can adduct to redox active protein thiols to induce oxidative posttranslational modifications that modulate protein and tissue function. OBJECTIVE: To investigate the role of oxidative protein modifications in 15d-PGJ(2)-mediated coronary vasodilation and define the distal signaling pathways leading to enhanced perfusion. METHODS AND RESULTS: Proteomic screening with biotinylated 15d-PGJ(2) identified novel vascular targets to which it adducts, most notably soluble epoxide hydrolase (sEH). 15d-PGJ(2) inhibited sEH by specifically adducting to a highly conserved thiol (Cys521) adjacent to the catalytic center of the hydrolase. Indeed a Cys521Ser sEH "redox-dead" mutant was resistant to 15d-PGJ(2)-induced hydrolase inhibition. 15d-PGJ(2) dilated coronary vessels and a role for hydrolase inhibition was supported by 2 structurally different sEH antagonists each independently inducing vasorelaxation. Furthermore, 15d-PGJ(2) and sEH antagonists also increased coronary effluent epoxyeicosatrienoic acids consistent with their vasodilatory actions. Indeed 14,15-EET alone induced relaxation and 15d-PGJ(2)-mediated vasodilation was blocked by the EET receptor antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE). Additionally, the coronary vasculature of sEH-null mice was basally dilated compared to wild-type controls and failed to vasodilate in response to 15d-PGJ(2). Coronary vasodilation to hypoxia in wild-types was accompanied by 15d-PGJ(2) adduction to and inhibition of sEH. Consistent with the importance of hydrolase inhibition, sEH-null mice failed to vasodilate during hypoxia. CONCLUSION: This represents a new paradigm for the regulation of sEH by an endogenous lipid, which is integral to the fundamental physiological response of coronary hypoxic vasodilation.
RATIONALE: 15-Deoxy-Δ-prostaglandin (15d-PG)J(2) is an electrophilic oxidant that dilates the coronary vasculature. This lipid can adduct to redox active protein thiols to induce oxidative posttranslational modifications that modulate protein and tissue function. OBJECTIVE: To investigate the role of oxidative protein modifications in 15d-PGJ(2)-mediated coronary vasodilation and define the distal signaling pathways leading to enhanced perfusion. METHODS AND RESULTS: Proteomic screening with biotinylated 15d-PGJ(2) identified novel vascular targets to which it adducts, most notably soluble epoxide hydrolase (sEH). 15d-PGJ(2) inhibited sEH by specifically adducting to a highly conserved thiol (Cys521) adjacent to the catalytic center of the hydrolase. Indeed a Cys521Ser sEH "redox-dead" mutant was resistant to 15d-PGJ(2)-induced hydrolase inhibition. 15d-PGJ(2) dilated coronary vessels and a role for hydrolase inhibition was supported by 2 structurally different sEH antagonists each independently inducing vasorelaxation. Furthermore, 15d-PGJ(2) and sEH antagonists also increased coronary effluent epoxyeicosatrienoic acids consistent with their vasodilatory actions. Indeed 14,15-EET alone induced relaxation and 15d-PGJ(2)-mediated vasodilation was blocked by the EET receptor antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE). Additionally, the coronary vasculature of sEH-null mice was basally dilated compared to wild-type controls and failed to vasodilate in response to 15d-PGJ(2). Coronary vasodilation to hypoxia in wild-types was accompanied by 15d-PGJ(2) adduction to and inhibition of sEH. Consistent with the importance of hydrolase inhibition, sEH-null mice failed to vasodilate during hypoxia. CONCLUSION: This represents a new paradigm for the regulation of sEH by an endogenous lipid, which is integral to the fundamental physiological response of coronary hypoxic vasodilation.
Authors: Volker Rudolph; Tanja K Rudolph; Francisco J Schopfer; Gustavo Bonacci; Steven R Woodcock; Marsha P Cole; Paul R S Baker; Ravi Ramani; Bruce A Freeman Journal: Cardiovasc Res Date: 2010-01-01 Impact factor: 10.787
Authors: Eduardo Barbosa-Sicard; Timo Frömel; Benjamin Keserü; Ralf P Brandes; Christophe Morisseau; Bruce D Hammock; Thomas Braun; Marcus Krüger; Ingrid Fleming Journal: J Biol Chem Date: 2009-08-24 Impact factor: 5.157
Authors: Benjamin Keserü; Eduardo Barbosa-Sicard; Ralph T Schermuly; Hiromasa Tanaka; Bruce D Hammock; Norbert Weissmann; Beate Fisslthaler; Ingrid Fleming Journal: Cardiovasc Res Date: 2010-01-01 Impact factor: 10.787
Authors: Eric E Kelley; Carlos I Batthyany; Nicholas J Hundley; Steven R Woodcock; Gustavo Bonacci; J Mauricio Del Rio; Francisco J Schopfer; Jack R Lancaster; Bruce A Freeman; Margaret M Tarpey Journal: J Biol Chem Date: 2008-10-29 Impact factor: 5.157
Authors: W Swardfager; M Hennebelle; D Yu; B D Hammock; A J Levitt; K Hashimoto; A Y Taha Journal: Neurosci Biobehav Rev Date: 2018-02-02 Impact factor: 8.989
Authors: Rebecca L Charles; Olena Rudyk; Oleksandra Prysyazhna; Alisa Kamynina; Jun Yang; Christophe Morisseau; Bruce D Hammock; Bruce A Freeman; Philip Eaton Journal: Proc Natl Acad Sci U S A Date: 2014-05-19 Impact factor: 11.205
Authors: William G Sanders; Christophe Morisseau; Bruce D Hammock; Alfred K Cheung; Christi M Terry Journal: Am J Physiol Cell Physiol Date: 2012-05-23 Impact factor: 4.249
Authors: Javier Barallobre-Barreiro; Shashi K Gupta; Anna Zoccarato; Rika Kitazume-Taneike; Marika Fava; Xiaoke Yin; Tessa Werner; Marc N Hirt; Anna Zampetaki; Alessandro Viviano; Mei Chong; Marshall Bern; Antonios Kourliouros; Nieves Domenech; Peter Willeit; Ajay M Shah; Marjan Jahangiri; Liliana Schaefer; Jens W Fischer; Renato V Iozzo; Rosa Viner; Thomas Thum; Joerg Heineke; Antoine Kichler; Kinya Otsu; Manuel Mayr Journal: Circulation Date: 2016-08-24 Impact factor: 29.690